

# ESMO VIRTUAL ADVANCED COURSE PROGRAMME

## KRAS targeting in NSCLC

28-29 November 2022

---

**CO-CHAIRS:** Myung-Ju Ahn, Korea  
Federica Di Nicolantonio, Italy

**SPEAKERS:** Mariano Barbacid, Spain  
Keith M. Kerr, United Kingdom  
Hye Ryun Kim, Korea  
Se-Hoon Lee, Korea  
Shun Lu, China  
Laura Mezquita, Spain  
Misako Nagasaka, United States  
Takashi Seto, Japan  
Ferdinandos Skoulidis, United States  
Daniel S. W. Tan, Singapore

### LEARNING OBJECTIVES

---

- Understanding the function and biology of KRAS in normal and malignant cells
- Gaining insights in the spectrum of KRAS molecular aberrations, platforms and strategies for molecular testing
- In depth discussion of emerging therapeutic strategies and clinical research in KRAS mutated NSCLC
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of KRAS G12C inhibition and beyond

**All timings are to be considered GMT+8 (Singapore Local Time)**

### Monday, 28 November 2022

---

15:00-15:10 **Welcome and introduction**  
10' Myung-Ju Ahn, KR  
Federica Di Nicolantonio, IT

15:10-16:45 **Session 1 – KRAS Biology, Epidemiology, Pathology**

20' The structure, function and role of KRAS in normal cell homeostasis  
Mariano Barbacid, ES

20' Epidemiology of KRAS activating mutations: Incidence and biology across tumours with emphasis on lung cancer  
Takashi Seto, JP

20' Molecular landscape of KRAS mutant NSCLC (molecular concomitant genetic alterations in KRAS mutant tumours)  
Se-Hoon Lee, KR

- 20' Pathology and molecular testing of NSCLC for KRAS mutations: who, how and when? (tissue, liquid biopsy)  
Keith M. Kerr, UK
- 15' Discussion
- 16:45-17:00 *Break*
- 17:00-18:35 **Session 2 – Targeting KRAS G12C in Lung Cancer**
- 20' Clinical development of KRAS G12C inhibitors – where are we now?  
Shun Lu, CN
- 20' Resistance to KRAS G12C inhibitors – what do we know?  
Daniel S. W. Tan, SG
- 20' Moving forward with KRAS G12C inhibitors – combinations (only chemotherapy and targeted therapy sequencing)  
Ferdinandos Skoulidis, US
- 15' Discussion
- 20' Clinical cases and Expert Panel Discussion
- 10' with discussion – single agent case with liver toxicity, Shun Lu, CN
- 10' with discussion – combination therapy, Ferdinandos Skoulidis, US

## Tuesday, 29 November 2022

---

- 15:00-16:15 **Session 3 – Moving beyond KRAS G12C**
- 20' Targeting KRAS beyond G12C – what is coming?  
Hye Ryun Kim, KR
- 20' Targeting KRAS with checkpoint inhibitors  
Laura Mezquita, ES
- 20' Vaccine and adoptive cell therapy strategies for the treatment of KRAS mutant NSCLC  
Misako Nagasaka, US
- 15' Discussion
- 16:15-16:30 *Break*

16:30-18:00

**Workshop Sessions**

10' Introduction based on clinical cases presented by speakers

20' Discussion

**Workshop 1**

Liquid biopsy applications for RAS-mutated mutational profiling, monitoring of disease course, clonal evolution and resistance in NSCLC

30'

Laura Mezquita, ES

Keith M. Kerr, UK

**Workshop 2**

Moving forward with KRAS G12C inhibitors in early stage/locally advanced NSCLC

30'

Shun Lu, CN

Daniel S. W. Tan, SG

**Workshop 3**

Designing practice-changing trials – key considerations

30'

Myung-Ju Ahn, KR

Federica Di Nicolantonio, IT

18:00-18:15

**Synthesis and wrap-up**

Myung-Ju Ahn, KR

Federica Di Nicolantonio, IT